US FDA declines to approve Aldeyra's drug for eye disorder
March 17 (Reuters) - The U.S. Food and Drug Administration on Tuesday declined to approve Aldeyra Therapeutics' ALDX.O drug for a type of eye disease, the company said. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sherry Jacob-Phillips) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Alcon AG
See all newsSwiss stocks - Factors to watch on November 12
Alcon AG reports results for the quarter ended September 30 - Earnings Summary
Alcon shares fall as tighter eye-care market outlook raises growth concerns (updated)
Alcon seen down after sales miss, tighter outlook
Swiss stocks - Factors to watch on November 11